JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Sana Biotechnology Inc

Suletud

SektorTervishoid

5.36 -3.77

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.22

Max

5.55

Põhinäitajad

By Trading Economics

Sissetulek

-44M

-94M

Kasumimarginaal

-321.09

Töötajad

194

EBITDA

-48M

-95M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+47.58% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. nov 2025

Turustatistika

By TradingEconomics

Turukapital

609M

1.4B

Eelmine avamishind

9.13

Eelmine sulgemishind

5.36

Uudiste sentiment

By Acuity

50%

50%

176 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. okt 2025, 23:28 UTC

Kuumad aktsiad

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29. okt 2025, 23:07 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13%

30. okt 2025, 00:00 UTC

Tulu

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29. okt 2025, 23:40 UTC

Tulu

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29. okt 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29. okt 2025, 23:25 UTC

Tulu

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29. okt 2025, 22:51 UTC

Tulu

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29. okt 2025, 22:45 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29. okt 2025, 22:09 UTC

Tulu

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29. okt 2025, 22:08 UTC

Market Talk
Tulu

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29. okt 2025, 21:58 UTC

Tulu

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29. okt 2025, 21:58 UTC

Tulu

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29. okt 2025, 21:57 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29. okt 2025, 21:54 UTC

Tulu

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29. okt 2025, 21:46 UTC

Tulu

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29. okt 2025, 21:43 UTC

Tulu

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29. okt 2025, 21:43 UTC

Tulu

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29. okt 2025, 21:41 UTC

Tulu

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29. okt 2025, 21:40 UTC

Tulu

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29. okt 2025, 21:39 UTC

Tulu

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

47.58% tõus

12 kuu keskmine prognoos

Keskmine 8.25 USD  47.58%

Kõrge 12 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

176 / 373 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat